AXLRx Book a callCommission

Rare Disease · GCC (Gulf) · In-Market

GCC IgA Nephropathy KOL Mapping

GCC IgA nephropathy expertise concentrates in five named tertiary centres. Roughly 300 practising nephrologists work the region, of whom 30 to 50 carry glomerular-disease subspecialty interest. This workbook sizes that concentrated institutional base before any individual name enters it.

Assess this report See what's inside ↓ Reviewed by Mark W, Commercial Analyst Last updated July 2026
Market United Kingdom GCC (Gulf) Stage

Key takeaways

  • 5 named tertiary GCC institutions performing the kidney biopsy IgAN diagnosis requires: KFSH&RC, Hamad Medical Corporation Doha, AUH, King Fahd Hospital Jeddah, University Hospital Sharjah
  • 300 practicing GCC nephrologists, of whom 30-50 carry glomerular-disease subspecialty interest
  • 5-10 recognised national GCC IgAN KOLs, the addressable specialist population for pre-launch engagement
  • 6 KOL Mapping gates (K1-K6), each independently verified before a name enters the workbook

Five named tertiary centres and a private-hospital channel of four groups define the addressable GCC IgA nephropathy network, against a base of roughly 300 nephrologists and 5 to 10 recognised national KOLs.

GCC IgA nephropathy diagnosis and treatment concentrate at a small set of tertiary institutions: KFSH&RC, Saudi Arabia's largest glomerular-disease programme, Hamad Medical Corporation in Doha, AUH, King Fahd Hospital in Jeddah, and University Hospital Sharjah. Kidney biopsy, the confirmatory step IgAN diagnosis requires, is available only at these centres, structurally capping the addressable population to patients who reach specialist nephrology care. Of the roughly 300 nephrologists practicing across the GCC, only 30 to 50 carry glomerular-disease subspecialty interest, and the recognised national KOL list runs to just 5 to 10 individuals. Our KOL Universe gate (K1) starts by sizing this concentrated institutional base before scoring any single physician.

A second, faster-moving channel sits alongside the public tertiary centres: private hospital groups, American Hospital Dubai, Burjeel, Saudi German, and Mouwasat, that have begun prescribing budesonide (Tarpeyo) ahead of GCC-wide formulary listing and represent the fastest access channel for a newly registered agent. Neither Tarpeyo nor sparsentan (Filspari) is SFDA-registered as of 2024, so hospital-by-hospital access decisions, not a national formulary, currently determine which institution a manufacturer must engage first. Our Tier Classification gate (K2) scores public-tertiary and private-channel institutions separately, since their influence over prescribing runs through different committee structures, and no named individual enters the workbook without a verification tag checked against live institutional-affiliation records.

The GCC IgA nephropathy network: five named tertiary centres and a four-group private hospital channel

INSTITUTIONAL STRUCTURE
InstitutionLocationChannel
KFSH&RCRiyadh, Saudi ArabiaPublic tertiary; Saudi Arabia's largest glomerular-disease programme
Hamad Medical CorporationDoha, QatarPublic tertiary referral centre
AUHUAEPublic tertiary referral centre
King Fahd HospitalJeddah, Saudi ArabiaPublic tertiary referral centre
University Hospital SharjahSharjah, UAEPublic tertiary referral centre
American Hospital Dubai, Burjeel, Saudi German, MouwasatUAE / Saudi ArabiaPrivate hospital channel; fastest current access route for a newly registered agent

Sources: Saudi Society of Nephrology membership data; GCC nephrology congress programme 2023; SFDA drug registration database query; Gulf Nephrology Society formulary review 2023; NPHC exceptional access framework documentation.

What this workbook answers

Every section answers a named commercial question your team is asking, scoped to your asset.

  1. Which GCC institutions actually perform the kidney biopsy IgAN diagnosis requires, and how concentrated is that network? • The five named tertiary centres (KFSH&RC, Hamad Medical Corporation Doha, AUH, King Fahd Hospital Jeddah, University Hospital Sharjah) • institutional concentration as a KOL-tiering signal • K1 KOL Universe Sizing methodology
  2. How does AXLRx tier the public tertiary-centre network against the faster-moving private hospital channel? • K2 Tier Classification methodology separating public and private-channel institutions • American Hospital Dubai, Burjeel, Saudi German, and Mouwasat as the private-channel comparator set • K3 Scientific Influence scoring inputs
  3. What verification standard does every named institution or KOL have to clear before shipping in the workbook? • The three-tag verification protocol (Verified/Industry benchmark/Requires client validation) • live publication and institutional-affiliation cross-checks • why no placeholder name ships unflagged
What's inside

Rare Disease · 24–32 pp · In-Market · Analyst report + Excel model + PowerPoint readout

  1. 1 · The Binding Constraint 2 pp
    • Why institutional concentration across five named tertiary centres, not scattergun individual outreach, is the single variable this workbook sizes first
    • Pressure-tested against the public-tertiary versus private-hospital channel split before the rest of the workbook is built out
  2. 2 · KOL Universe (K1) 4 pp
    • Every GCC IgAN institutional stakeholder and KOL sized and sourced from institutional-affiliation and registration data
    • The five named tertiary centres and the four-group private hospital channel as the sizing anchor
    • Universe boundaries: recognised national KOL versus high-volume prescriber
  3. 3 · Tier Classification (K2) 3 pp
    • Scientific-influence scoring across public-tertiary and private-channel institutions
    • What separates a national KOL from a high-volume community prescriber
  4. 4 · Scientific Influence (K3) 3 pp
    • Influence inputs: institutional role, glomerular-disease subspecialty status, private-channel prescribing activity
    • Cross-checked against independent institutional and registration data
  5. 5 · Engagement Readiness (K4) 3 pp
    • Readiness scoring and channel recommendations per institution
    • Sequencing implications given the empty GCC formulary and hospital-by-hospital access route
  6. 6 · MSL Territory Coverage (K5) 3 pp
    • Territory-to-institution coverage map across Saudi Arabia, Qatar, and the UAE
    • Where current MSL deployment has gaps
  7. 7 · Cross-Border Network (K6) 3 pp
    • Multi-market reach for institutions and KOLs active beyond a single GCC state
    • Implications for coordinated versus purely local engagement
  8. 8 · Client Alignment Questions 2 pp
    • The open KOL-engagement questions your medical affairs team must close
    • Structured for an internal alignment session before MSL deployment

Appendix and source ledger included · 45-minute analyst readout included with delivery

Custom workbook delivered in 72 hours.

Assess this report

Included with every brief

PDF
PDF Brief
KOL Mapping Brief — Summary Edition
PDF summary brief: tier strip, KOL universe table, and institutional breakdown for GCC IgA nephropathy.
XLS
Excel Model
KOL Mapping Workbook — Excel
6-sheet editable workbook: KOL Universe, Tier Scoring, Engagement Calendar, MSL Territory, Cross-Border Network, Evidence Register.

Get Started

Commission this workbook

AXLRx delivers KOL mapping workbooks built for medical affairs and commercial teams engaging GCC IgA nephropathy specialists ahead of SFDA registration. Custom workbook in 72 hours.

  1. 1. Submit your requestSpecify your indication, geography, and institution scope.
  2. 2. Scoping callAXLRx analyst confirms institution scope and verification standard before building.
  3. 3. DeliveryResearch-verified KOL workbook in 72 hours with optional analyst readout.
Assess this report View sample workbooks

How AXLRx builds this workbook

Prepared by MoatRx analysts on the AXLRx commercial consulting engine.

Every AXLRx KOL workbook is built from live institutional-affiliation and registration data, not secondary summaries. No KOL name or institution ships without a verification tag.

GCC IgA nephropathy KOL sources: Saudi Society of Nephrology membership data, the GCC nephrology congress programme 2023, the SFDA drug registration database, and the Gulf Nephrology Society formulary review 2023.

  • Named tertiary institution list verified against Saudi Society of Nephrology membership data and the GCC nephrology congress programme 2023
  • Nephrologist and subspecialty counts verified against Saudi Society of Nephrology membership data
  • SFDA registration status for budesonide and sparsentan verified against the SFDA drug registration database query
  • Every KOL and institutional entry in the underlying workbook carries a three-tag verification status before delivery: Verified, Industry benchmark, or Requires client validation

Frequently asked questions

Deliverables What formats are included with every workbook?

Every commissioned KOL Mapping workbook includes an editable 6-sheet Excel workbook (KOL Universe, Tier Scoring, Engagement Calendar, MSL Territory, Cross-Border Network, Evidence Register) and a PDF summary brief. No PowerPoint deck; this deliverable is built to be worked in directly. An optional 45-minute analyst readout call is included.

Sources How are institutional roles and KOL rankings verified?

Every entry is built from live institutional-affiliation and registration data, then tagged Verified, Industry benchmark, or Requires client validation. No name ships unverified.

Customisation Can I scope this to a specific institution set or GCC state?

Yes. The intake form captures your indication, geography, and institution scope. A scoping call confirms scope before research starts. Commission via the intake form to start.